BidaskClub upgraded shares of Amarin (NASDAQ:AMRN) from a sell rating to a hold rating in a research report released on Thursday, BidAskClub reports.

Other research analysts also recently issued reports about the company. Roth Capital set a $31.00 price target on Amarin and gave the company a buy rating in a research note on Friday, September 6th. Zacks Investment Research downgraded Amarin from a buy rating to a hold rating in a research note on Wednesday, July 24th. Jefferies Financial Group set a $30.00 price target on Amarin and gave the company a buy rating in a research note on Tuesday, September 3rd. Cantor Fitzgerald set a $35.00 price target on Amarin and gave the company a buy rating in a research note on Tuesday, September 3rd. Finally, Leerink Swann set a $26.00 price target on Amarin and gave the company a buy rating in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $29.50.

Shares of NASDAQ:AMRN traded up $0.04 during mid-day trading on Thursday, reaching $16.79. 2,059,410 shares of the stock were exchanged, compared to its average volume of 6,576,359. The company has a quick ratio of 1.76, a current ratio of 2.01 and a debt-to-equity ratio of 0.18. The company has a market cap of $5.83 billion, a P/E ratio of -43.05 and a beta of 1.27. Amarin has a one year low of $2.65 and a one year high of $23.91. The stock’s 50 day simple moving average is $16.08 and its 200-day simple moving average is $18.42.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.02) by $0.01. The firm had revenue of $100.40 million during the quarter, compared to the consensus estimate of $99.54 million. Amarin had a negative return on equity of 111.75% and a negative net margin of 27.51%. The business’s revenue was up 90.9% compared to the same quarter last year. During the same period last year, the company earned ($0.10) earnings per share. Analysts anticipate that Amarin will post -0.2 EPS for the current fiscal year.

In other news, Director Lars Ekman sold 91,016 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $15.01, for a total value of $1,366,150.16. Following the completion of the sale, the director now directly owns 13,500 shares of the company’s stock, valued at $202,635. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Aaron Berg sold 113,195 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The shares were sold at an average price of $18.59, for a total value of $2,104,295.05. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 659,202 shares of company stock valued at $13,058,754. Corporate insiders own 2.75% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in AMRN. Wealthcare Advisory Partners LLC acquired a new stake in shares of Amarin in the first quarter valued at approximately $42,000. Kistler Tiffany Companies LLC lifted its position in shares of Amarin by 166.7% in the second quarter. Kistler Tiffany Companies LLC now owns 2,400 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 1,500 shares during the last quarter. Tobam lifted its position in shares of Amarin by 45.5% in the second quarter. Tobam now owns 3,200 shares of the biopharmaceutical company’s stock valued at $62,000 after buying an additional 1,000 shares during the last quarter. Global Retirement Partners LLC lifted its position in shares of Amarin by 30.7% in the first quarter. Global Retirement Partners LLC now owns 3,414 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 802 shares during the last quarter. Finally, Quantamental Technologies LLC acquired a new stake in shares of Amarin in the second quarter valued at approximately $74,000. 47.94% of the stock is owned by institutional investors.

About Amarin

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Further Reading: What does the Producer Price Index (PPI) tell investors?

Analyst Recommendations for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.